Patents Assigned to Imperium Biotechnologies, Inc.
  • COMPUTATIONAL DESIGN OF IDEOTYPICALLY MODULATED PHARMACOEFFECTORS FOR SELECTIVE CELL TREATMENT
    Publication number: 20140195216
    Abstract: In system and method embodiments, an embodiment includes the collection, input, and organization of target nucleotide source or sources; the identification of potential target sequences for ideotypically modulated pharmacoeffectors (IMP); the exclusion, prioritization, or deprioritization of target sequences on the basis of undesirable binding for ideotypically modulated pharmacoeffectors (IMP); and/or the design of targeting sequences on the basis of reverse complementarity or sequence complementarity. IMPs are designed for optimal use in respective applications, including cancers, autoimmune diseases, infectious diseases, cellular diseases, and other applications.
    Type: Application
    Filed: January 8, 2013
    Publication date: July 10, 2014
    Applicant: Imperium Biotechnologies, Inc.
    Inventor: Jacob Jennings Orme
  • IDEOTYPICALLY MODULATED PHARMACOEFFECTORS FOR SELECTIVE CELL TREATMENT
    Publication number: 20140057351
    Abstract: In a method embodiment, a method includes introducing a plurality of Ideotypically Modulated Pharmacoeffectors (IMP) into a population of cells. Each IMP may include a detection domain and an activation domain. One or more epitopes is bound by the detection domain. The activation domain is activated in response to the binding. Applications may include but are not limited to viral infections, other intracellular infections, cancers, vector-borne diseases, autoimmune diseases, cellular diseases, cellular enhancement, and research.
    Type: Application
    Filed: August 26, 2013
    Publication date: February 27, 2014
    Applicant: Imperium Biotechnologies, Inc.
    Inventor: Jacob Jennings Orme
  • System for selective cell treatment using ideotypically modulated pharmacoeffectors
    Patent number: 8518409
    Abstract: In a method embodiment, a method includes introducing a plurality of Ideotypically Modulated Pharmacoeffectors (IMP) into a population of cells. Each IMP may include a detection domain and an activation domain. One or more epitopes is bound by the detection domain. The activation domain is activated in response to the binding. Applications may include but are not limited to viral infections, other intracellular infections, cancers, vector-borne diseases, autoimmune diseases, cellular diseases, cellular enhancement, and research.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: August 27, 2013
    Assignee: Imperium Biotechnologies, Inc.
    Inventor: Jacob Orme
  • Methods of using ideotypically modulated pharmacoeffectors for selective cell treatment
    Patent number: 8383405
    Abstract: In a method embodiment, a method includes introducing a plurality of Ideotypically Modulated Pharmacoeffectors (IMP) into a population of cells. Each IMP may include a detection domain and an activation domain. One or more epitopes is bound by the detection domain. The activation domain is activated in response to the binding. Applications may include but are not limited to viral infections, other intracellular infections, cancers, vector-borne diseases, autoimmune diseases, cellular diseases, cellular enhancement, and research.
    Type: Grant
    Filed: May 31, 2010
    Date of Patent: February 26, 2013
    Assignee: Imperium Biotechnologies, Inc.
    Inventor: Jacob Orme